REPL
Replimune Group IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$485.94M
P/E Ratio
—
EPS
$-3.44
Beta
0.74
52W High
$13.24
52W Low
$2.68
50-Day MA
$7.59
200-Day MA
$7.60
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Replimune Group Inc
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-318.88M |
| Operating Margin | 0.00% |
| Return on Equity | -90.90% |
| Return on Assets | -43.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.64 |
| Price-to-Book | 3.30 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.24 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $82.57M |
| Float | $62.90M |
| % Insiders | 2.17% |
| % Institutions | 97.27% |
Analyst Ratings
Consensus ($12.86 target)
1
Strong Buy4
Buy2
HoldData last updated: 4/9/2026